Abstract
The hemoregulatory peptide (pGlu-Glu-Asp-Cys-Lys, pEEDCK) is a potent inhibitor of stem cell recruitment, which is a major source of hematological complications after cytostatic tumor therapy. By preventing recruitment, pEEDCK can keep hemopoietic stem cells in their normal nonproliferative state and in this way prevent damage by certain cell cycle-specific cytostatic drugs. pEEDCK could play a role as hemoprotector in tumor chemotherapy. As a thiol-containing peptide, pEEDCK is highly sensitive to oxidation, resulting in the formation of a dimer. Although monomeric pEEDCK is a strong inhibitor of colony-forming units-granulocyte/macrophage (CFU-GM) clonal growth, the dimer was previously found to enhance colony-stimulating factor-triggered CFU-GM colony formation. It seemed, thus, necessary to find methods that avoid undesired dimerization reactions. A solid phase strategy for pEEDCK synthesis is presented. The primary synthetic product, S-tert-butyl-sulfenyl-pEEDCK, was purified and stored with the thiol-protecting group remaining attached. Conversion to active monomeric pEEDCK was achieved by reductive treatment in situ before application and removal of tert-butyl-mercaptane in vacuo. The activation reagent (dithioerythritol) prevented reoxidation also in culture media, where unprotected peptide was oxidized rapidly (t1/2 less than 13 min). The purified synthetic peptide was found to be a potent inhibitor of CFU-GM colony formation (IC50 = 1.1 x 10(-12) M) in vitro. It was also found to inhibit colony formation of some leukemic cell lines (HL-60, RAJI) although at much higher concentrations (10(-8) to 10(-9) M). Friend leukemia cells were not inhibited in the dose range where CFU-GM were sensitive.
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|